Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
Autoimmune diseases of the nervous system | D020274 | — | — | — | 1 | — | — | — | 1 |
Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Nervous system malformations | D009421 | HP_0000707 | Q00-Q07 | — | 1 | — | — | — | 1 |
Drug common name | CENSAVUDINE |
INN | censavudine |
Description | Censavudine (INN) (BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023.
|
Classification | Small molecule |
Drug class | antineoplastics; antivirals (zidovudine group) (exception: edoxudine) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C#C[C@@]1(CO)C=C[C@H](n2cc(C)c(=O)[nH]c2=O)O1 |
PDB | — |
CAS-ID | 1097733-37-3 |
RxCUI | — |
ChEMBL ID | CHEMBL124363 |
ChEBI ID | — |
PubChem CID | 3008897 |
DrugBank | — |
UNII ID | 6IE83O6NGA (ChemIDplus, GSRS) |